DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations

被引:46
作者
Cuzzolin, Alberto [1 ]
Sturlese, Mattia [1 ]
Malvacio, Ivana [2 ]
Ciancetta, Antonella [1 ]
Moro, Stefano [1 ]
机构
[1] Univ Padua, Mol Modeling Sect, Dept Pharmaceut & Pharmacol Sci, I-35131 Padua, Italy
[2] Univ Nacl Cordoba, INFIQC Organ Chem Dept, Sch Chem Sci, RA-5000 Cordoba, Argentina
关键词
molecular docking; docking benchmark; virtual screening; structure-based drug design; PROTEIN-LIGAND DOCKING; STRUCTURE-BASED DESIGN; KINASE INHIBITORS; ACCURATE DOCKING; CHK1; INHIBITORS; OPTIMIZATION; DISCOVERY; POTENT; PROGRAMS; PLANTS;
D O I
10.3390/molecules20069977
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Virtual screening (VS) is a computational methodology that streamlines the drug discovery process by reducing costs and required resources through the in silico identification of potential drug candidates. Structure-based VS (SBVS) exploits knowledge about the three-dimensional (3D) structure of protein targets and uses the docking methodology as search engine for novel hits. The success of a SBVS campaign strongly depends upon the accuracy of the docking protocol used to select the candidates from large chemical libraries. The identification of suitable protocols is therefore a crucial step in the setup of SBVS experiments. Carrying out extensive benchmark studies, however, is usually a tangled task that requires users' proficiency in handling different file formats and philosophies at the basis of the plethora of existing software packages. We present here DockBench 1.0, a platform available free of charge that eases the pipeline by automating the entire procedure, from docking benchmark to VS setups. In its current implementation, DockBench 1.0 handles seven docking software packages and offers the possibility to test up to seventeen different protocols. The main features of our platform are presented here and the results of the benchmark study of human Checkpoint kinase 1 (hChk1) are discussed as validation test.
引用
收藏
页码:9977 / 9993
页数:17
相关论文
共 45 条
[1]  
[Anonymous], GOLD SUIT VERS 5 2
[2]  
[Anonymous], 2011, Virtual Screening: Principles, Challenges, and Practical Guidelines
[3]   Chk1 and Chk2 kinases in checkpoint control and cancer [J].
Bartek, J ;
Lukas, J .
CANCER CELL, 2003, 3 (05) :421-429
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]   Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors [J].
Brnardic, Edward J. ;
Garbaccio, Robert M. ;
Fraley, Mark E. ;
Tasber, Edward S. ;
Steen, Justin T. ;
Arrington, Kenneth L. ;
Dudkin, Vadim Y. ;
Hartman, George D. ;
Stirdivant, Steven M. ;
Drakas, Bob A. ;
Rickert, Keith ;
Walsh, Eileen S. ;
Hamilton, Kelly ;
Buser, Carolyn A. ;
Hardwick, James ;
Tao, Weikang ;
Beek, Stephen C. ;
Mao, Xianzhi ;
Lobell, Robert B. ;
Sepp-Lorenzino, Laura ;
Yan, Youwei ;
Ikuta, Mari ;
Munshi, Sanjeev K. ;
Kuo, Lawrence C. ;
Kreatsoulas, Constantine .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (21) :5989-5994
[6]  
Chemical Computing Group Inc, 2015, MOL OP ENV MOE
[7]   Alternative Quality Assessment Strategy to Compare Performances of GPCR-Ligand Docking Protocols: The Human Adenosine A2A Receptor as a Case Study [J].
Ciancetta, Antonella ;
Cuzzolin, Alberto ;
Moro, Stefano .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2014, 54 (08) :2243-2254
[8]   Comparing protein-ligand docking programs is difficult [J].
Cole, JC ;
Murray, CW ;
Nissink, JWM ;
Taylor, RD ;
Taylor, R .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2005, 60 (03) :325-332
[9]   Development of thioquinazolinones, allosteric Chk1 kinase inhibitors [J].
Converso, Antonella ;
Hartingh, Timothy ;
Garbaccio, Robert M. ;
Tasber, Edward ;
Rickert, Keith ;
Fraley, Mark E. ;
Yan, Youwei ;
Kreatsoulas, Constantine ;
Stirdivant, Steve ;
Drakas, Bob ;
Walsh, Eileen S. ;
Hamilton, Kelly ;
Buser, Carolyn A. ;
Mao, Xianzhi ;
Abrams, Marc T. ;
Beck, Stephen C. ;
Tao, Weikang ;
Lobell, Rob ;
Sepp-Lorenzino, Laura ;
Zugay-Murphy, Joan ;
Sardana, Vinod ;
Munshi, Sanjeev K. ;
Jezequel-Sur, Sylvie Marie ;
Zuck, Paul D. ;
Hartman, George D. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (04) :1240-1244
[10]   Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates [J].
Dudkin, Vadim Y. ;
Rickert, Keith ;
Kreatsoulas, Constantine ;
Wang, Cheng ;
Arrington, Kenneth L. ;
Fraley, Mark E. ;
Hartman, George D. ;
Yan, Yowei ;
Ikuta, Mari ;
Stirdivant, Steven M. ;
Drakas, Robert A. ;
Walsh, Eileen S. ;
Hamilton, Kelly ;
Buser, Carolyn A. ;
Lobell, Robert B. ;
Sepp-Lorenzino, Laura .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (07) :2609-2612